Dialysis world news


Man who contracted rare bug during dialysis treated at Carlisle's Cumberland ... - News Star

Medics at the Cumberland Infirmary in Carlisle have treated a patient who picked up a rare form of the E.coli bug while having dialysis in Egypt.

Cumberland Infirmary photo

A report on the man’s condition presented to senior managers at the hospital trust which treated him reveals that medics believe he caught the bug during a trip to the North African country in December last year.

None of his contacts was found to have caught the infection and the national watchdog Public Health England (PHE) has been told which dialysis centre in Egypt was involved.

The bug – known as CPE – was one of a number discussed in a report considered by the board of North Cumbria University Hospitals NHS Trust, which runs both the infirmary and Whitehaven’s West Cumbria Hospital.

The report goes on to mention other infections which have been dealt with by the trust’s two hospitals – including nine cases of the bug C-diff, six at the Cumberland Infirmary and three at the West Cumberland.

During 2014-15, says the report, there were 120 patients across north Cumbria with C-diff, and of these 19 died within 30 days of diagnosis.

Between April and June, there were 31 patients affected by the bug, and four of these died within 30 days.

PHE and the Lancashire Health Protection team confirmed that they were involved in investigating a case of CPE at North Cumbria University Hospitals NHS Trust.

Their investigation began in April and centred on Cumberland Infirmary and Whitehaven’s West Cumberland Hospital after routine testing uncovered the bug.

In line with national guidelines, people who may have come into contact with the patient were traced and no other cases were detected.

CPE belongs to a group of bacteria normally found in humans and animal guts. However if they enter blood or the urinary tract, they can cause very serious infections, said the statement. This can occur after an injury or via the use of medical devices such as catheters or intravenous drips where the skin is punctured.

CPE is the name given to gut bacteria which have developed resistance to an important group of antibiotics called Carbapenems. Infections caused by these CPE bacteria can still be treated with antibiotics but this is more difficult and may require combinations of drugs or use of older antibiotics.

Although some people can have active infection, others may carry the bacteria but have no symptoms. This bacteria can spread through faecal contamination so it is very important to practise good hand hygiene to stop it spreading to other vulnerable people. The incident was closed in June 2015.

...

 
Company Shares of NxStage Medical, Inc. Rally 2.44% - American Trade Journal

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) rose by 2.44% in the past week and 0.21% for the last 4 weeks. The shares have outperformed the S&P 500 by 1.26% in the past week but underperformed the index by 1.08% in the last 4 weeks. Nxstage Medical, Inc. has dropped 21.84% during the last 3-month period . Year-to-Date the stock performance stands at -20.36%.

The company shares have rallied 6.17% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $14.55 and the 200 day moving average is recorded at $16.79. S&P 500 has rallied 8.5% during the last 52-weeks. The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares have been rated as hold from 1 Wall Street Analysts. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $14.05 and hit $14.59 on the upside , eventually ending the session at $14.28, with a gain of 2.07% or 0.29 points. The heightened volatility saw the trading volume jump to 399,829 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $903 million. The 52-week low of the share price is at $11.5 . Currently the company Insiders own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -5.19% in the total insider ownership. Institutional Investors own 95.4% of Company shares. During last 3 month period, -0.93% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 2,000 shares at an average price of $13.86 in a transaction dated on July 22, 2015. The total value of the transaction was worth $27,720. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...

 
Isis Pharmaceuticals, Astrazeneca to develop antisense therapies for ... - News-Medical.net

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney.

Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production by targeting RNA to either prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins.

AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals plus development and regulatory milestones for each programme that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each programme.

Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca, said:

Antisense-based therapies are rapidly gaining momentum in the clinic and becoming an important component of our early stage pipeline. This collaboration combines the world-class antisense drug research capabilities of Isis with our expertise in cardiovascular, metabolic and renal disease drug discovery and development. By working together, we aim to uncover targets and pathways that can be manipulated using antisense drug therapy.

B. Lynne Parshall, Chief Operating Officer at Isis Pharmaceuticals, said:

This expansion of our collaboration with AstraZeneca establishes our second strategic relationship. This new collaboration will help broaden the application of our antisense technology to targets in the kidney. AstraZeneca is committed to finding novel best-in-class therapies for some of the largest, most complex and fastest growing disease segments in the developed world. Combining our antisense technology with AstraZeneca's strong knowledge, leadership and commitment in these areas should be very valuable in fully exploiting these opportunities and moving new therapies effectively and efficiently toward the market.

This transaction is subject to clearances under the Hart-Scott Rodino Antitrust Improvements Act.

http://www.astrazeneca.com/

...

 
Company Shares of Fresenius Medical Care Corporation Drops by -5.5% - News Watch International

Fresenius Medical Care Corporation (NYSE:FMS) has lost 5.5% during the past week and dropped 1.11% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 6.59%. Fresenius Medical Care Corporation (NYSE:FMS) has underperformed the index by 2.38% in the last 4 weeks. Investors should watch out for further signals and trade with caution. Fresenius Medical Care AG & Co. KGAA has dropped 1.79% during the last 3-month period . Year-to-Date the stock performance stands at 11.25%.

The company shares have rallied 20.93% in the past 52 Weeks. On June 4, 2015 The shares registered one year high of $44.34 and one year low was seen on October 16, 2014 at $32.4. The 50-day moving average is $42.55 and the 200 day moving average is recorded at $41.2. S&P 500 has rallied 8.5% during the last 52-weeks. The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. The shares have been rated as hold from 4 Wall Street Analysts. 1 analysts have suggested buy for the company. Shares of Fresenius Medical Care Corporation (NYSE:FMS) ended Friday session in red amid volatile trading. The shares closed down 0.14 points or 0.34% at $40.9 with 97,639 shares getting traded. Post opening the session at $41.22, the shares hit an intraday low of $40.84 and an intraday high of $41.31 and the price vacillated in this range throughout the day. The company has a market cap of $25,534 million and the number of outstanding shares have been calculated to be 624,304,000 shares. The 52-week high of Fresenius Medical Care Corporation (NYSE:FMS) is $44.34 and the 52-week low is $32.4. Institutional Investors own 2% of Company shares. During last 3 month period, 1.28% of total institutional ownership has changed in the company shares. Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patients peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers. NO COMMENTS LEAVE A REPLY Cancel reply

...

 
Company Shares of Rockwell Medical, Inc. Drops by -9.03% - American Trade Journal

Company Shares of Rockwell Medical, Inc. Drops by -9.03%
American Trade Journal
Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis ...
Rockwell Medical (RMTI) Scheduled to Post Earnings on Tuesday Dakota Financial News

all 2 news articles »

...

 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 27 of 2630
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.